Evidence map›Paper›PMID 38372369›Full record

ArticleJournal of visualized experiments : JoVE2024

Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells.

Ines Cherkaoui, Qian Du, Dieter Egli, Shivani Misra, Guy A Rutter

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. A loss of function variant inmedRxiv : the preprint server for health sciences · 2026
    Article
  2. Investigating the pathogenicity of the recessivemedRxiv : the preprint server for health sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

Ines CherkaouiDepartment of Metabolism, Digestion and Reproduction, Faculty of Medicine, Cell Biology and Functional Genomics; i.cherkaoui20@imperial.ac.uk.
Qian DuDepartments of Pediatrics, Naomi Berrie Diabetes Center, Obstetrics and Gynecology, Columbia Stem Cell Initiative, Columbia University Irving Medical Center, Columbia University.
Dieter EgliDepartments of Pediatrics, Naomi Berrie Diabetes Center, Obstetrics and Gynecology, Columbia Stem Cell Initiative, Columbia University Irving Medical Center, Columbia University.
Shivani MisraDepartment of Metabolism, Digestion and Reproduction, Faculty of Medicine, Cell Biology and Functional Genomics; Department of Diabetes, Imperial College Healthcare NHS Trust.
Guy A RutterDepartment of Metabolism, Digestion and Reproduction, Faculty of Medicine, Cell Biology and Functional Genomics; Faculté de Médicine, Université de Montréal; Lee Kong Chian Imperial Medical School, Nanyang Technological University; guy.rutter@umontreal.ca.
Columbia University · USImperial College Healthcare NHS Trust · GBUniversité de Montréal · CA

Funding

Enhancer-based Immune and Beta Cell Dysregulation Underlying T1D RiskR01DK127778 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EGLI, DIETER MEINRAD, ROSENFELD, MICHAEL G · 2020 to 2023
$4.5M
NIDDK NIH HHS R01 DK127778
6 · The paper itself

Abstract

Human pluripotent stem cells (hPSCs) can differentiate into any kind of cell, making them an excellent alternative source of human pancreatic β-cells. hPSCs can either be embryonic stem cells (hESCs) derived from the blastocyst or induced pluripotent cells (hiPSCs) generated directly from somatic cells using a reprogramming process. Here a video-based protocol is presented to outline the optimal culture and passage conditions for hPSCs, prior to their differentiation and subsequent generation of insulin-producing pancreatic cells. This methodology follows the six-stage process for β-cell directed differentiation, wherein hPSCs differentiate into definitive endoderm (DE), primitive gut tube, posterior foregut fate, pancreatic progenitors, pancreatic endocrine progenitors, and ultimately pancreatic β-cells. It is noteworthy that this differentiation methodology takes a period of 27 days to generate human pancreatic β-cells. The potential of insulin secretion was evaluated through two experiments, which included immunostaining and glucose-stimulated insulin secretion.

Indexed as

Induced Pluripotent Stem CellsInsulin-Secreting CellsPluripotent Stem CellsCell DifferentiationHumansPancreas

Identifiers

PMID38372369
PMCPMC13038044
OpenAlexW4391873038

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.